Condition P03

Children and adolescents with obesity

Participants aged 6 to 17 years with obesity by age and sex specific BMI criteria.

7 randomized trials; 16 fitted analyses across 9 outcomes.

Headline results

For each primary outcome, the analysis that pools all doses of each medicine, with the three most favorable estimates against the common comparator. Open an analysis for every treatment, dose and check.

BMI standard deviation score change

Mean difference versus Placebo; weeks 40 to 104 (target week 68); 2 trials

Semaglutide injection-0.96 (-1.27 to -0.54)
Liraglutide injection-0.23 (-0.55 to 0.12)

Lower values favor the treatment.

All outcomes

Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.

BMI standard deviation score changeprimary

O13A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 40 to 104 (target week 68)	Treatment policy	Each dose separately	2	3	Network meta-analysis
weeks 40 to 104 (target week 68)	Treatment policy	Doses of a drug pooled	2	3	Network meta-analysis
weeks 40 to 104 (target week 68)	Not stated by the trials	Doses of a drug pooled	1	2	Descriptive only
weeks 40 to 104 (target week 68)	Not stated by the trials	Each dose separately	1	2	Descriptive only
weeks 20 to 40 (target week 26)	Treatment policy	Doses of a drug pooled	1	2	Descriptive only
weeks 20 to 40 (target week 26)	Treatment policy	Each dose separately	1	2	Descriptive only

Percent body weight changeprimary

O10

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 40 to 104 (target week 68)	Not stated by the trials	Doses of a drug pooled	2	2	Pairwise meta-analysis
weeks 40 to 104 (target week 68)	Not stated by the trials	Each dose separately	2	2	Pairwise meta-analysis
weeks 40 to 104 (target week 68)	Treatment policy	Each dose separately	1	2	Descriptive only
weeks 20 to 40 (target week 26)	Not stated by the trials	Doses of a drug pooled	1	2	Descriptive only
weeks 20 to 40 (target week 26)	Not stated by the trials	Each dose separately	1	2	Descriptive only
weeks 40 to 104 (target week 68)	Treatment policy	Doses of a drug pooled	1	2	Descriptive only

Percent BMI change

O13B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 40 to 104 (target week 68)	Not stated by the trials	Doses of a drug pooled	2	3	Network meta-analysis
weeks 40 to 104 (target week 68)	Not stated by the trials	Each dose separately	2	3	Network meta-analysis
weeks 40 to 104 (target week 68)	Treatment policy	Doses of a drug pooled	1	2	Descriptive only
weeks 40 to 104 (target week 68)	Treatment policy	Each dose separately	1	2	Descriptive only

Serious adverse events

O25

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	5	5	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis

Discontinuation due to adverse events

O26

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	2	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	2	2	Descriptive only

Nausea

O27A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	5	5	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis

Vomiting

O27B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	4	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	5	5	Network meta-analysis

Diarrhea

O27C

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	4	4	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	4	5	Network meta-analysis

Constipation

O27D

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	3	4	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled	3	4	Network meta-analysis